Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium salicylate is a nonsteroidal anti-inflammatory drug (NSAID) and the sodium salt of salicylic acid. It acts primarily by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which leads to its analgesic, antipyretic, and anti-inflammatory effects[1][5][6]. Sodium salicylate may also activate mitogen-activated protein kinase (p38MAPK), inducing apoptosis in cancer cells[1]. It is used as an alternative to aspirin for individuals sensitive to that drug and has been investigated for use in pain relief, fever reduction, inflammation control, and as a urinary tract analgesic[3][5]. Additionally, it exhibits bacteriostatic and fungicidal properties[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sodium salicylate.